Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

March 16, 2025

Primary Completion Date

March 16, 2026

Study Completion Date

March 16, 2027

Conditions
Prostate CA
Interventions
DRUG

Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy

On the 1st to 5th day, Fasudil hydrochloride (10mg of fasudil hydrochloride) was treated, and on the 5th day, PD-1 monoclonal antibody (triprilizumab, 3mg/kg, intravenous drip) was treated. The treatment was repeated every 21 days for a total of 4 times

DRUG

Placebo combined with androgen deprivation therapy

Days 1 to 5 were treated with placebo (0.9% sodium chloride 10mg), and days 5 were treated with placebo (0.9% sodium chloride 3mg/kg). The treatment was repeated every 21 days for a total of 4 times.

PROCEDURE

radical prostatectomy

Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle

All Listed Sponsors
lead

baotai Liang

OTHER

NCT06861192 - Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer | Biotech Hunter | Biotech Hunter